Cue Biopharma Reports $1.08 Per Share Loss in Q1 Amidst Going Concern Doubts
CUE has more than doubled off its 52-week low of $4.971 on light trading volume (0.2× avg).
Summary
Cue Biopharma reported a first-quarter loss of $1.08 per share. This financial update follows the company's 10-K filing in March, which disclosed substantial doubt about its ability to continue as a going concern and a cash runway extending only into Q1 2027. Just two days prior, a PRE 14A filing revealed the company is seeking shareholder approval for a highly dilutive private placement and a new equity incentive plan. The reported loss underscores the ongoing financial challenges and highlights the urgency of the proposed capital raise to address its liquidity needs. Traders will be monitoring the outcome of the shareholder vote on the private placement and any further updates on the company's operational runway.
At the time of this announcement, CUE was trading at $26.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $82.5M. The 52-week trading range was $4.97 to $41.42. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.